Company Name: Vemanti Group Inc. Stock Symbol: VMNT Company Website: vemanti.com Trading at approx $0.55 Per Share (11/22/2016)
VMNT is a brand new cannabis stock with business operations moving fast and the company is already generating revenue. MedicatedOne, LLC, a Vemanti wholly-owned subsidiary, is a a California-based medical cannabis company. The company is engaged in the research, development, and licensing of natural cannabis products. Currently, MedicatedOne has 6 different products for sale (CBD Popcorn, CBD Capsules, CBD Oil drops, CBD Chewing gum, CBD Suppositories, CBD Mints) According to recent news, Vemanti is preparing to launch a new wholly-owned subsidiary, which will look to provide a comprehensive mobile commerce and payments service for the emerging cannabis industry and also the company’s subsidiary, MedicatedOne is developing a new line of innovative cannabis-infused edible products, For details on MedicatedOne, LLC, and company products visit: medicatedone.com About Vemanti Group
Vemanti Group, Inc. (VMNT) is a diversified holding corporation that’s looking to be active in high-growth and technology-driven markets. The company plans to grow by adding value-added and fundamentally-sound businesses to their portfolio. Currently Vemanti Group has two subsidiaries, MedicatedOne LLC, a California-based medical cannabis company, and VoiceStep Telecom, LLC, a Voice-over-IP (VoIP) and Fax-over-IP (FoIP) service provider. For details on Vemanti Group, Inc. and its portfolio, visit: vemanti.com Recent News & Corporate Developments:
Vemanti Group Plans New Mobile Commerce and Payments Subsidiary
Vemanti Group’s MedicatedOne Announces New Line of Cannabis-Infused Edibles
Vemanti Group’s MedicatedOne Starts Shipping Its Cannabis-Infused Product
Vemanti Group Announces Corporate Developments
Vemanti Group Completes Acquisition of MedicatedOne research of VMNT at: stockpicksnyc.com/VMNT
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.